1Maloney DG,Smith B,Rose A.Rituximab:mechanism of action and resistance.Semin Oncol,2002,29(Suppl 2):2-9.
2Chan OT,Madaio MP,Shlomchik MJ.B cells are required for lupus nephritis in the polygenic,Fas-intact URL model of systemic autoimmunity.J Immunol,1999,163:3592-3596.
3Ferry H,Jones M,Vaux DJ,et al.The cellular location of selfantigen determines the positive and negative selection of autoreactive B cells.J Exp Med,2003,198:1415-1425.
4Looney R J,Anolik J,Sanz I.B lymphocytes in systemic lupus erythematosus:lessons from therapy targeting B cells.Lupus,2004,13:381-390.
5Looney RJ,Anojik JH,Campbell D,et al.B cell depletionas a novel treatment for systemic lupus erythematosus:a phase Ⅰ /Ⅱ dose-escalation trial of rituximab.Arthritis Rheum,2004,50:2580-2589.
6Leandro M J,Edwards JC,Cambridge G,et al.An open study of B lymphocyte depletion in systemic lupus erythermatosus.Arthritis Rheum,2002,46:2673-2677.
7Sfikakis PP,Boletis JN,Lionaki S,et al.Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand.Arthritis Rheum,2005,52:501-513.
8Leandro M J,Cambridge G,Edwards JC,et al.B-cell depletion in the treatment of patients with systemic lupus erythematosus:a longitudinal analysis of 24 patients.Rheumatology,2005,44:1542-1545.
9Tokunaga M,Fujii K,Saito K,et al.Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.Rheumatology,2005,44:176-182.
10Van Vollenhoven RF,Gunnarsson I,Welin-Henriksson E,et al.Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.Scand J Rheumatol,2004,33:423-427.
3GracianoML, Cavaglieri R, DelleH, et al. Intrarenal rennin angiotensin system is up regulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis[J]. J Am Soc Nephrol, 2004,15 (7) : 1805-1815.
4Remuzzi G, Bertani T. Pathophysiology of progressiven hrop- athies[J]. N Engl J Med, 1998,339 (20) : 1448-1456.
5Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue anglo tensinconverting enzyme:manifestationsin mechanistic and endpo int data[J]. Am J Cardio l,2001, 88(9A):1220.
